HELX
Franklin Genomic Advancements ETF
Price Chart
Latest Quote
$36.63
+0.00 (+0.00%)
Current Price
| Previous Close | $36.63 |
| Open | $35.92 |
| Day High | $36.63 |
| Day Low | $35.92 |
| Volume | 31 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.40% |
| Net Assets | $23.02M |
| Expense Ratio | 0.50% |
| Category | Health |
| Fund Family | Franklin Templeton Investments |
| Net Asset Value | $36.63 |
| Premium/Discount | 0.01% |
| Quarterly Dividend Yield | 0.40% |
| P/E Ratio | 32.09 |
| Exchange | BTS |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $35.57 |
| SMA50 | $34.50 |
| SMA200 | $34.43 |
| RSI | 72.47 |
| ATR | 0.5822 |
| Rel Volume | 0.34 |
Performance History
| Week | +6.71% |
| Month | +11.19% |
| Quarter | +19.66% |
| 6 Months | +3.86% |
| YTD | +4.26% |
| Year | +40.23% |
| 3 Years | +22.65% |
| 5 Years | -15.83% |
| 10 Years | +59.93% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $38.03 | 185 |
| 2026-06-23 | $36.63 | 3,100 |
| 2026-06-22 | $36.33 | 400 |
| 2026-06-18 | $36.49 | 100 |
| 2026-06-17 | $36.04 | 100 |
| 2026-06-16 | $35.64 | 100 |
| 2026-06-15 | $35.82 | 3,900 |
| 2026-06-12 | $35.45 | 100 |
| 2026-06-11 | $35.71 | 300 |
| 2026-06-10 | $34.97 | 100 |
| 2026-06-09 | $35.36 | 100 |
| 2026-06-08 | $34.67 | 100 |
| 2026-06-05 | $34.80 | 100 |
| 2026-06-04 | $35.74 | 700 |
| 2026-06-03 | $34.67 | 100 |
| 2026-06-02 | $34.31 | 500 |
| 2026-06-01 | $35.05 | 500 |
| 2026-05-29 | $35.43 | 200 |
| 2026-05-28 | $35.63 | 100 |
| 2026-05-27 | $34.71 | 100 |
| 2026-05-26 | $34.39 | 100 |
About Franklin Genomic Advancements ETF
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.